CIK 0000887359
- Large accelerated filer
Vericel Corp
Sign in to watch- Ticker
- VCEL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- MI
- Entity type
- Operating
- EIN
- 943096597
- Phone
- +1 617-588-5555
- Business address
- 25 BLUE SKY DRIVE, BURLINGTON, MA, 01803
- Former names
- AASTROM BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,896,581
- in 8 filings, $5.8M under 10b5-1 plans
Net −$5,896,581. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Mara Joseph Anthony Jr −$4.1M Chief Financial Officer sold 82% of stake
- Flynn Sean C. −$779K Chief Legal Officer sold 88% of stake
- MCLAUGHLIN KEVIN F −$413K Director sold 28% of stake
- ZERBE ROBERT L MD −$386K Director sold 19% of stake
- SIEGAL JONATHAN −$188K Principal Accounting Officer sold 73% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-24 | Flynn Sean C. Chief Legal Officer | Sale 10b5-1 | −1,474 | $45.84 | $68K | 487 |
| 2024-06-21 | Flynn Sean C. Chief Legal Officer | Sale 10b5-1 | −6,772 | $45.02 | $305K | 487 |
| 2024-06-20 | Flynn Sean C. Chief Legal Officer | Sale 10b5-1 | −6,754 | $45.04 | $304K | 487 |
| 2024-06-13 | Colangelo Dominick President and CEO | Sale 10b5-1 | −17,500 | $43.10 | $754K | 220,752 |
| 2024-06-12 | Colangelo Dominick President and CEO | Sale 10b5-1 | −17,500 | $44.12 | $772K | 220,752 |
| 2024-05-20 | Hopper Jonathan Mark Chief Medical Officer | Sale 10b5-1 | −10,000 | $49.99 | $500K | 58,116 |
| 2024-05-16 | Colangelo Dominick President and CEO | Sale 10b5-1 | −17,500 | $47.85 | $837K | 220,752 |
| 2024-05-15 | Colangelo Dominick President and CEO | Sale 10b5-1 | −17,500 | $49.67 | $869K | 220,752 |
| 2024-04-18 | Colangelo Dominick President and CEO | Sale 10b5-1 | −17,500 | $44.59 | $780K | 195,307 |
| 2024-04-17 | Colangelo Dominick President and CEO | Sale 10b5-1 | −17,500 | $46.47 | $813K | 195,307 |
| 2024-03-27 | ZERBE ROBERT L MD Director | Sale 10b5-1 | −3,278 | $51.57 | $169K | 23,395 |
| 2024-03-14 | Colangelo Dominick President and CEO | Sale 10b5-1 | −17,500 | $44.02 | $770K | 194,870 |
| 2024-03-13 | Colangelo Dominick President and CEO | Sale 10b5-1 | −17,500 | $44.67 | $782K | 194,870 |
| 2024-03-11 | Halpin Michael Chief Operating Officer | Sale 10b5-1 | −7,874 | $44.71 | $352K | 949 |
| 2024-03-08 | Flynn Sean C. SVP, General Counsel | Sale 10b5-1 | −8,115 | $45.33 | $368K | 167 |
| 2024-03-08 | Flynn Sean C. SVP, General Counsel | Sale | −8,115 | $45.33 | $368K | 167 |
| 2024-03-07 | SIEGAL JONATHAN Principal Accounting Officer | Sale | −1,634 | $45.00 | $74K | 1,400 |
| 2024-02-20 | ZERBE ROBERT L MD Director | Sale 10b5-1 | −722 | $50.01 | $36K | 23,395 |
| 2024-02-15 | Colangelo Dominick President and CEO | Sale 10b5-1 | −17,500 | $48.85 | $855K | 174,008 |
| 2024-02-14 | Colangelo Dominick President and CEO | Sale 10b5-1 | −17,500 | $46.99 | $822K | 174,008 |
Page 6 of 14 · 279 trades